TEVA PHARMACEUTICALS MARK A GOSHKO MEMORIAL GRANTS
Administered by the American Chemical Society

Eligibility, Terms, and Conditions

1. An applicant must be a tenured faculty member of a PhD-granting department in the United States, and have received his/her first tenure decision during or after the 2012-2013 academic year.

2. Research must be conducted in the area of organic chemistry, with potential or direct connections with medicinal or pharmaceutical chemistry, such that the successful results would be of practical benefit to the discovery of organic compounds useful as human medicines.

3. Grants are awarded for $100,000 per year for a period of three years (September 1, 2018 to August 31, 2021), and subject to annual review and approval of progress.

4. Budget restrictions:
   a. No institutional overhead charges, nor facilities and administrative expenses may be charged to the grant.
   b. A maximum of $10,000 per grant year, or $30,000 total, may be used to support the principal investigator’s salary. Postdoctoral fellows, research associates, technicians, graduate students (stipend and/or tuition), and/or undergraduate students may be supported through the grant, at levels commensurate with the grantees department or academic unit.
   c. A maximum of $5,000 per year may be used for travel, including travel to conferences or symposia, or to collaborating laboratories. Travel to present research results must be budgeted for the third year; see item 8 below.
   d. The proposed budget, should the proposal be funded, will become the approved grant budget and any changes require prior approval of the ACS Office of Research Grants.
   e. Of the support given, funds remaining at the end of each grant year may be carried forward into the next.

5. The institution, by acceptance of this grant, provides assurance that support normally provided by the institution for research of the faculty member will not be diminished.

6. Acceptance of an ACS Teva Pharmaceuticals Mark A Goshko Grant will be conditioned upon agreement by the grantees institution that in the event the principal investigator is unable for any reason to conduct the research proposed, the funds, if previously paid by the American Chemical Society, shall, upon demand, be returned in full to the Society, and, further, that in the event the principal investigator is unable for any reason to continue with the research after it has commenced, this grant shall be terminated at once and the unexpended and unencumbered balance of any funds theretofore advanced shall be returned to the Society.

7. Annual financial and scientific progress reports are required. ACS shall, in its sole discretion and consistent with its standard practices, determine whether the grant recipient is meeting the goals and objectives appropriately.

8. Each grant recipient will be required to present a lecture during or promptly following the grant period at a time and place to be agreed upon by the grant recipient and the ACS. Travel costs in connection with the lecture should be budgeted in the travel category for the third year.

02/2018